Newsletter Signup x
Acute pancreatitis is highly inflammatory pancreatic disease. It becomes a life threatening complication of childhood leukaemia treatment caused by the anti-leukemic drug Asparaginase. Once children develop acute pancreatitis, they cannot receive any more Asparaginase, because most likely the pancreatitis will happen again. Without Asparaginase treatments, the options for management of children with leukaemia are limited. Previously, attempts have been made to improve the Asparaginase treatment by changing the source of bacteria or other modifications of the protein. However, these changes have not given the expected results. One of the reasons was the absence, until now, of the fundamental study of the mechanism of Asparaginase-induced pancreatitis.
Modification of the Asparaginase-based drugs for ALL
Dr Oleg Gerasimenko
Cardiff University
Cardiff
1 June 2018
36 months
£245,507